Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HUGE CALL dino!
Hey JMC$ almost missed you there my friend. You look slick in those sunglasses man :)
Yes, my friend lol. The Pumpers are coming The Pumpers are coming. All I need now is a horse! Happy to hear you doing well MiamiGent. You are one of the tops on I_hub.
Well, the future HUGE Companies have to start on the OTC as babies. The great thing is we trade OTCQB
Yeah and a very strong close at 0525 :) BIG SMILE!
Beautiful call there TommyBoy!
Maybe. Should reopen for around $39
Halted again at 34.95 hod. AMAZING!!!!!!!!!
Should reopen for around $33
There he is MiamiGent. Been awhile, buddy!
Looking good
Yea man, I agree. I'm interested in hearing updates from this S Korea project. HYSR is sitting on tons of cash so maybe these S Korean guys have something real in the pipeline and if they do then "WATCH OUT" the stock will explode like it did in 2020. :)
I dunno. Anything is possible.
After a day of much-anticipated profit-taking yesterday, DRCT is now heading northbound again!
The registrant had 1,197,258 shares of its common stock, $0.0001 par value per share, outstanding as of November 13, 2023.
lmao
Mack Trucks’ customers will now have access to Blink’s EV equipment specially designed and optimized for fleets.
Miami Beach, Fla., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global manufacturer, owner, operator and provider of electric vehicle (EV) charging equipment and services, today announced it has been selected as a full-service EV infrastructure provider for Mack Trucks through Mack’s Vendor Direct Ship and Turnkey Solutions program.
Mack Trucks selected Blink and its reliable, scalable EV equipment and extensive fleet expertise. As operators look to electrify their fleets, Blink and its advanced EV charging products provide dedicated expertise to help accurately assess particular fleet needs to optimize infrastructure services and provide end-to-end software solutions. Additionally, Blink has commenced deploying workplace chargers at multiple Volvo and Mack facilities nationwide.
“We applaud the efforts of Mack for their forward-thinking in advancing fleet electrification and we are excited to be selected as a charging partner in their Turnkey Solutions program, providing reliable and advanced charging solutions,” said Jim Nemec, Chief Revenue Officer at Blink Charging. “Building a dependable charging infrastructure is vital in keeping electric fleets operational and on the road. We look forward to continuing to work with Mack as they move to bring e-mobility to fleets around the country.”
Mack Trucks' Turnkey Solutions program covers all phases of infrastructure development. Encompassing initial site consultations, acquisition of charging hardware and software, permit procurement, installation processes, liaising with utility companies, and maintenance of the charging equipment. It also helps fleets find incentives and write grant proposals.
“Our charging partnerships and the Turnkey Solutions program as a whole will enable customers to more easily manage the development and installation of infrastructure for the Mack MD Electric and Mack LR Electric vehicles,” said Ryan Saba, Mack energy solutions manager. “The strategic partnerships Mack has in place will aid customers with support, including charger uptime. This is a key differentiator for Mack since charging components continue to be difficult to secure.”
This news follows Blink’s robust third-quarter results, evidencing a notable increase in revenues by 152%, totaling approximately $43.4 million, and a surge in gross profits by 167% to roughly $12.8 million in contrast to Q3 2022. Blink also announced plans to expand operations in the United Kingdom and Ireland by launching its advanced EQ 200 charger, continuing its global expansion initiative.
###
About Blink Charging
Blink Charging Co. (Nasdaq: BLNK), a global leader in electric vehicle (EV) charging equipment, has contracted, sold, or deployed nearly 85,000 charging ports worldwide, many of which are networked EV charging stations, enabling EV drivers to easily charge at any of Blink’s charging locations. Blink’s principal line of products and services includes the Blink EV charging network (“Blink Network”), EV charging equipment, EV charging services, and the products and services of recent acquisitions, including SemaConnect, Blue Corner, BlueLA and Envoy. The Blink Network uses proprietary, cloud-based software that operates, maintains, and tracks the EV charging stations connected to the network and the associated charging data. With global EV purchases forecasted to half of passenger cars sold in the US by 2030, Blink has established key strategic partnerships for rolling out adoption across numerous location types, including parking facilities, multifamily residences and condos, workplace locations, health care/medical facilities, schools and universities, airports, auto
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos
LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, today announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration (FDA) for treating severe obstructive sleep apnea (OSA) in adults using the Vivos’ removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances. Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance.
As a result of this FDA clearance, Vivos becomes the first company ever to have approved and bring to market a clear alternative treatment to CPAP or surgical neurostimulation implants for patients with severe OSA. This latest clearance comes just eleven months after the FDA granted Vivos 510(k) clearance for the DNA oral appliance to treat mild-to-moderate OSA, and represents the first time the FDA has ever granted an oral appliance a clearance to treat moderate and severe OSA in adults, 18 years of age and older along with positive airway pressure (PAP) and/or myofunctional therapy, as needed.
Nationally renowned medical sleep specialist, author and lecturer, Dr. David McCarty, MD, elaborated on the impact of this landmark decision, stating “Make no mistake: this is a huge development on the landscape of treatments for OSA. As the medical profession has gained a better understanding of the complex factors contributing to OSA, we now recognize that a critical component to this condition is the form and functionality of the oral vault. This is where medical collaboration with an airway-centered dentistry approach like Vivos offers is a game-changer. This decision by the FDA could be life changing for patients who suffer from severe OSA and for whom other treatments have failed.”
Kirk Huntsman, Chairman and CEO of Vivos, stated, “This achievement is a pivotal milestone for Vivos, and elevates our proven treatment options right into the mainstream of sleep medicine. It is even more important for the millions of severe OSA patients who are desperate for an effective alternative treatment. Before this, severe OSA patients’ only realistic treatment options were CPAP, neurostimulation implants or other invasive surgeries. Today, they have what we believe is a far more desirable option that is very affordable and doesn’t require surgery or a lifetime of nightly use and intervention.”
“Vivos trained providers can now treat patients with OSA and conditions associated with OSA comprehensively using our suite of FDA cleared devices, without regard to the severity of their OSA condition and across a range of price point options,” continued Mr. Huntsman. “We believe this unprecedented decision by the FDA will generate broader acceptance throughout the medical community for Vivos treatment options, leading to the potential for higher patient referrals and case starts as well as collaboration with medical professionals. We also believe it will enhance our value proposition to third-party distribution partners such as durable medical equipment (DME) companies. This approval could also clear the way for greater reimbursement levels from medical insurance payors and Medicare. We believe that all these factors should favorably impact our ability to grow our revenues in 2024 and beyond.”
The statistically significant data submitted to the FDA from 73 severe OSA patients showed that 80% of patients experienced an improvement of at least 1 classification or at least a 50% improvement in the Apnea Hypopnea Index (AHI), and 97% of patients improved or stayed the same. Average treatment time was just 9.7 months. Treatment results with severe sleep apnea patients were actually better than with mild and moderate patients. All pre- and post-treatment testing was conducted with no device in the mouth. Unlike all other oral appliances on the market, Vivos’ proprietary CARE appliances gradually reposition the hard and soft tissues that define the airway, thereby opening it up and optimizing its function and flow.
In a separate peer reviewed study published in the Journal of Sleep Medicine in 2022, 1 out of 4 Vivos patients experienced a complete resolution of their OSA symptoms. Vivos believes its products represent the first time that an effective resolution of OSA has been clearly demonstrated over a limited treatment time, unlike the lifetime intervention required for CPAP or surgical neurostimulation implants.
No persistent safety issues were found in any patient cohort published or submitted to date, although some patients required aligners following treatment.
https://ml.globenewswire.com/Resource/Download/93fa4580-447f-476d-a8e7-fe3bfab4a76f
Vivos DNA appliance®
https://ml.globenewswire.com/Resource/Download/8906a168-b7af-44e4-a33c-f63db4815e21
Vivos mRNA appliance®
https://ml.globenewswire.com/Resource/Download/68667c88-4eb7-4510-99d5-7b50235555cf
Vivos mmRNA appliance®
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to severe OSA. It has proven effective in approximately 40,000 patients treated worldwide by more than 1,850 trained dentists.
The Vivos Method includes treatment regimens that employ the proprietary Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.
Chinese Hospitals Are Housing Another Deadly Outbreak
Authorities are covering up the spread of antibiotic-resistant pneumonia.
https://foreignpolicy.com/2023/11/28/chinese-hospitals-pandemic-outbreak-pneumonia/
LMFAO!!
Believe me, I'm used to that. A bunch of puss pimples head moma boy's basement dwellers
I dunno if these guys really have something new but here is the news for you
180 Life Sciences Announces Review of Strategic Alternatives
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options.
There is no assurance that the strategic review process will result in the approval or completion of any specific transaction or outcome.
180 Life Sciences has not established a timeline for completion of the review process and does not intend to comment further unless and until its Board of Directors has approved a definitive course of action, or it is determined that other disclosure is necessary or appropriate.
I think so, Steve. JMC told me about it last night on the phone. The DD is just out of sight!!!!!!
Oh yea. You know that I know my math. LOL. I love this one.
That has been the new stock manipulation tool for many of these POS NASDAQ scams for like 6 months. Yea the SEC is watching porn and most likely spending the Government $$$$ on Prostitutes!
JMC$ I got 038 039 and 040. The stock looks fantastic. Love the volume and action. Thanks again my friend
Nice to meet ya TheKid5 :)
Thank you, Steve :)
I'm in. Thank you JMC
SunHydrogen’s CEO Tim Young Visits New South Korea Facility for Scale-Up of Company’s Green Hydrogen Technology
Press Release | 11/28/2023
CORALVILLE, IA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SunHydrogen, Inc. (OTCQB: HYSR), the developer of a breakthrough technology to produce renewable hydrogen using sunlight and water, today announced that the Company’s industrial partner, COTEC, has completed setup of a new laboratory space solely for the development of SunHydrogen’s manufacturing process.
SunHydrogen’s CEO Tim Young recently made a strategic visit to COTEC’s Changwon facility to view firsthand the progress at the newly-established laboratory dedicated to SunHydrogen’s technology. COTEC is poised to begin replicating SunHydrogen’s nanoparticle-based technology employing advanced industrial electroplating processes in this state-of-the-art facility. Meticulously set up by COTEC’s team, the laboratory is fully equipped with the necessary equipment, chemicals, and characterization techniques to accelerate SunHydrogen’s manufacturing process.
Within one of SunHydrogen’s hydrogen generators, billions of patented Photoelectrosynthetically Active Heterostructure (PAH) nanoparticles per square centimeter split apart water to generate hydrogen and oxygen. These PAH nanoparticles are composed of multiple layers of solar cells. The high-voltage, high-light absorbing properties of the solar cells enable the Company to make them ultrathin and with significantly fewer materials, lowering costs and raising efficiency. Together, SunHydrogen and COTEC will explore the development and implementation of electroplating solutions to translate SunHydrogen’s existing PAH architecture and process to manufacturing scale while maintaining low cost and high efficiency.
The Company expects its initial exploration with COTEC to be completed by December 31, 2023. Following this phase, SunHydrogen’s next step is to produce 1m² hydrogen panels to be utilized in multiple pilot projects showcasing the world’s first-ever nanoparticle-based green hydrogen production at commercial scale.
COTEC is a leader in industrial electroplating and electrochemical processes and is well-positioned to collaborate with SunHydrogen in this critical aspect of the Company’s scale-up process. COTEC possesses extensive plating expertise across the aerospace, automotive, defense and nuclear industries, and has worked with high-level clients such as Boeing, Hanwha, Airbus and more.
For photos from COTEC's facility, please view this press release on SunHydrogen's news feed at www.sunhydrogen.com/news.
A.H = HOD 12.83
SenesTech Launches EVOLVE Soft Bait Fertility Solution in California-based Ace Hardware Franchise Locations
PHOENIX, Nov. 27, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the leader in fertility control to manage animal pest populations, today announced the launch of Evolve™ Soft Bait ("Evolve") at Ace Hardware franchise locations in California. Evolve is the first and only soft bait product featuring breakthrough, next generation technology that targets rodent populations by using nonlethal methods to restrict fertility. The franchise has also recently began selling SenesTech's expanded line of fertility control products, including the Isolate™ and Elevate™ bait systems for ContraPest®. This marks the first time a traditional retail store has offered SenesTech's rodent fertility control solutions.
"California-based Scarborough Ace Hardware, as well as Scarborough Home and Garden, are the first retail outlets to commit to SenesTech's line. They will also be among the first in the U.S. to receive shipments of Evolve based on their recent preorder," commented Joel Fruendt, SenesTech's President and Chief Executive Officer. "We expect the penetration of retail and big box to rapidly accelerate, especially with the launch of Evolve and its retail friendly soft bait profile and packaging."
Evolve addresses the fundamental issue of rodent overpopulation by focusing on the rapid reproduction of rats. Evolve controls the population by reducing or eliminating the fertility of rats, rather than trying to keep up with the growing numbers of an infestation with poisons alone. The active ingredient in Evolve effectively reduces fertility in rodents in numerous independent studies. Evolve is highly palatable to rats, easy to deploy, offers diverse placement in many different environments and is priced competitively to rodenticide alternatives.
"Evolve was developed to offer customers a soft bait product that has similar efficacy to ContraPest, but in a format that is easier to deploy, and is ideally suited for use by do it yourself consumers. We are pleased to be partnering with the team at Scarborough Ace Hardware to provide their customers with an innovative solution to address their rodent issues," Fruendt expanded.
Crystal Maro from Scarborough Ace Hardware commented, "We put the ContraPest product line on the shelves recently and are already re-ordering due to high sales levels. The product is definitely starting to pick up, and with the Evolve soft bait now available, we expect interest and sales to accelerate. This area was overrun with rats after the CZU fire. Traps and poison can only get you so far, and both can cause harm to local wildlife and pets. People are very excited that there is an alternative."
Closed regular hours $12.47 with HOD $12.59 for 500% gains for November. And you can take that to the Bank!
Holy shit! $12.14
DRCT November stock of the month just crossed $11.00 its a bonanza!
Therapeutic Solutions International and Campbell Neurosciences Publish on Nutritional Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Non-Toxic Means of Addressing Depression
Patented QuadraMune® Product Shown to Modulate Biochemical Pathway Associated with Major Depressive Syndrome
ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), announced today a publication with Campbell Neurosciences and several academic institutions describing the importance of the indolamine 2,3 dioxygenase pathway in depression, as well as modulation of this pathway by QuadraMune®, a multi-patented nutraceutical that is commercially available.
The publication is freely available at PsyArXiv Preprints | Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Means of Treating Depression (osf.io).
“QuadraMune® was developed as an immune stimulator for the prevention and treatment of COVID-19 and was granted several patents for this indication1,2. Subsequently, the science behind QuadraMune® was validated by numerous independent institutions3,4,” said Thomas Ichim, Ph.D., President, and Chief Executive Officer of Campbell Neurosciences and Board Member of Therapeutic Solutions International. “Through its ability to suppress activation of the indolamine 2,3 dioxygenase pathway, as well as preliminary data reported in our publication, we are eager to explore the utility of this approach in the area of major depressive disorder”.
Campbell Neurosciences is a subsidiary of Therapeutic Solutions International and has developed a blood-based test for suicidal propensity, as well as several therapeutic approaches to immunologically address mental health.
“Depression resistant to conventional medication is considered to be a “Silent Epidemic” and affects up to one of three patients5,” said Noelle Ramos, first author of the publication and consultant to the Company. “Through combining the cutting-edge immunological experiences of Dr. Ichim, as well as the deep neurology and medical knowledge of the other coauthors, I am confident that this paper is a first step in shifting our perception of depression from a strictly biochemical disorder to a more immunological associated condition.”
“QuadraMune® is one of several approaches using science-based nutraceuticals developed by the Company,” said Timothy Dixon, President and CEO of Therapeutic Solutions International. “While we are usually reporting on medical advancements accomplished by our regenerative medicine division, the fact that we have products commercialized is an interesting aspect of our company that I suspect will be receiving more attention as the state of our progress advances. The caliber of the current paper’s co authors we see as a positive signal”.
Hitting new 52-week highs pre-markets $9.22
Rumor has it that you bought $1.80 last Friday.
Holy Stock Gods HOD $9.04 is a 350% gain for November!
A run to $8.00 is not out of the question for today currently $7.69
DRCT $7.33 hod new 52-week high